Becerril VLE, Hernández GME, Granados CI, Álvarez GL, Pérez TSM, Pavón RL

Idioma: Español
Referencias bibliográficas: 57
Paginas: 411-418
Archivo PDF: 405.36 Kb.

RESUMEN

Los Sistemas Nervioso, Endócrino e Inmunológico mantienen a través de la vía humoral y neuronal una comunicación permanente y concertada que incluye a las hormonas neurotransmisoras, las citocinas y a sus respectivos receptores expresados en las células que conforman estos tres sistemas. La variación de los niveles de estos mediadores solubles induce la regulación de varios procesos fisiológicos y media la respuesta de nuestro organismo ante la presencia de estímulos estresantes, tanto físicos como psicológicos. La activación crónica de la interacción neuroendocrinoinmunológica favorece la aparición de variaciones numéricas y funcionales en los tres sistemas involucrados y genera alteraciones de tipo conductual.
Entre las alteraciones conductuales más estudiadas destaca el llamado “sickness behavior”, que se caracteriza por la presencia de anedonia, fatiga, enlentecimiento psicomotor, disminución del apetito, alteraciones en el patrón del sueño y un incremento en la sensibilidad al dolor. Las similitudes entre los síntomas conductuales del “sickness behavior” y la depresión mayor han permitido establecer una hipótesis sobre la participación de las citocinas y otros factores inflamatorios en la fisiopatología de algunos trastornos neuropsiquiátricos como la depresión, la disfunción cognitiva, la fatiga, los trastornos de ansiedad, los de la personalidad y las enfermedades neurodegenerativas como las de Parkinson y de Alzheimer.
Las alteraciones conductuales presentes en la depresión mayor pueden ser inducidas por la administración individual o conjunta de citocinas proinflamatorias, de mitógenos o por agentes infecciosos que inducen una importante secreción de moléculas inflamatorias. Las variaciones periféricas y centrales de los mediadores inflamatorios influyen significativamente sobre los neurotransmisores como el glutamato, la dopamina, la serotonina, la proteína p38 MAPK y la indolomina-2-3 dioxigenasa (IDO).
Es por ello que actualmente las citocinas, los neurotransmisores al igual que las rutas metabólicas en las que participan son el blanco de nuevos tratamientos para algunos padecimientos psiquiátricos, lo que mejorará la calidad de vida para los pacientes.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Pavón L, Hernández M, Loria F, Sandoval-Lopez G et al. Interacciones neuroendocrinoinmunológicas. Salud Mental 2004;27(3):19-25.

2. Hernández M, Becerril E, Alvarez L, Pavón L. Vias de neuroinmunomodulación. Salud Mental 2007;30(6):13-19.

3. Paul E. Fundamental immunolog. Quinta edición. Philadelphia: 2003.

4. Haas HS, Schauenstein K. Neuroimmunomodulation via limbic structures--the neuroanatomy of psychoimmunology. Prog Neurobiol 1997;51:195-222.

5. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-741.

6. Andrews JA, Neises KD. Cells, biomarkers, and post-traumatic stress disorder: evidence for peripheral involvement in a central disease. J Neurochem 2012;120:26-36.

7. Dantzer R. Cytokine-induced sickness behavior: where do we stand? Brain Behav Immun 2001;15:7-24.

8. Kent S, Bluthe RM, Kelley KW et al. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992;13:24-28.

9. Harrison NA, Brydon L, Walker C et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009;66:407-414.

10. Harrison NA, Brydon L, Walker C et al. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009;66:415-422.

11. O’Connor JC, Lawson MA, Andre C et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009;14:511-522.

12. Dantzer R, O’Connor JC, Freund GG et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008;9:46-56.

13. Moreau M, Andre C, O’Connor JC et al. Inoculation of Bacillus Calmette- Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun 2008;22:1087-1095.

14. Castanon N, Bluthe RM, Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 2001;154:50-60.

15. Evans DL, Charney DS, Lewis L et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005;58:175-189.

16. Dowlati Y, Herrmann N, Swardfager W et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.

17. Bower JE, Ganz PA, Tao ML et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 2009;15:5534-5540.

18. Danese A, Moffitt TE, Pariante CM et al. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008;65:409-415.

19. Pavón L, Sandoval-López G, Eugenia Hernández M et al. Th2 cytokine response in Major Depressive Disorder patients before treatment. J Neuroimmunol 2006;172:156-165.

20. Raison CL, Borisov AS, Broadwell SD et al. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005;66:41-48.

21. Raison CL, Borisov AS, Majer M et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009;65:296-303.

22. Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004;56:819-824.

23. Capuron L, Ravaud A, Miller AH et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004;18:205-213.

24. Raison CL, Dantzer R, Kelley KW et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFNalpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010;15:393-403.

25. Capuron L, Pagnoni G, Demetrashvili MF et al. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007;32:2384-2392.

26. Kitagami T, Yamada K, Miura H et al. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003;978:104-114.

27. Zielasek J, Hartung HP. Molecular mechanisms of microglial activation. Adv Neuroimmunol 1996;6:191-122.

28. Moron JA, Zakharova I, Ferrer JV et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003;23:8480-8488.

29. Anisman H, Merali Z, Poulter MO et al. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005;11:963-972.

30. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001;344:961-966.

31. Lotrich FE, Ferrell RE, Rabinovitz M et al. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009;65:344-348.

32. Cai W, Khaoustov VI, Xie Q et al. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005;42:880-887.

33. Zhu CB, Blakely RD, Hewlett WA. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31:2121-2131.

34. Zhu CB, Lindler KM, Owens AW et al. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010;35:2510-2520.

35. Sanchez MM, Alagbe O, Felger JC et al. Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in rhesus monkeys. Mol Psychiatry 2007;12:895-897.

36. Fujigaki H, Saito K, Fujigaki S et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006;139:655-662.

37. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002;303:1-10.

38. Delgado PL, Price LH, Miller HL et al. Serotonin and the neurobiology of depression. Effects of tryptophan depletion in drug-free depressed patients. Arch Gen Psychiatry 1994;51:865-874.

39. Capuron L, Neurauter G, Musselman DL et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-914.

40. Capuron L, Ravaud A, Neveu PJ et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468- 473.

41. O’Connor JC, Lawson MA, Andre C et al. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive- like behavior. J Immunol 2009;182:3202-3212.

42. Wichers MC, Koek GH, Robaeys G et al. IDO and interferon-alphainduced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005;10:538-544.

43. Borland LM, Michael AC. Voltammetric study of the control of striatal dopamine release by glutamate. J Neurochem 2004;91:220-229.

44. Wu HQ, Rassoulpour A, Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm 2007;114:33-41.

45. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008;13:501-510.

46. Ida T, Hara M, Nakamura Y et al. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008;432:232-236.

47. Haydon PG, Carmignoto G. Astrocyte control of synaptic transmission and neurovascular coupling. Physiol Rev 2006;86:1009-1031.

48. D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 2009;29:2089-2102.

49. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007;6:219-233.

50. Tyring S, Gottlieb A, Papp K et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35.

51. Muller N, Schwarz MJ, Dehning S et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684.

52. Johnson BA 3rd, Baban B, Mellor AL. Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy 2009;1:645-661.

53. Boissier MC, Assier E, Falgarone G et al. Shifting the imbalance from Th1/Th2 to Th17/treg: the changing rheumatoid arthritis paradigm. Joint Bone Spine 2008;75:373-375.

54. Tesmer LA, Lundy SK, Sarkar S, et al. Th17 cells in human disease. Immunol Rev 2008;223:87-113.

55. aan het Rot M, Collins KA, Murrough JW et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-145.

56. Li N, Lee B, Liu RJ et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010;329:959-964.

57. Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008;29:565-577.